November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.
Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.
Dana-Farber/Brigham and Women’s Cancer Center formally announced an exclusive, expanded collaboration to increase access to DF/BWCC experts and resources for patients at Stamford Health’s Carl & Dorothy Bennett Cancer Center.
Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.
Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.
Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.
Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.
Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.
Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.
Caron Jacobson, MD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.
Sara M. Tolaney, MD, MPH, discusses escalating versus de-escalating therapies in HER2-positive breast cancer.
Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.
Sara M. Tolaney, MD, MPH, discusses the challenges in treating patients with heterogenous HER2 expression and what treatments could potentially improve outcomes for this subgroup.
Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia and ongoing research in the space.
Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.
Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.
Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.
Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.
Toni Choueiri, MD, discusses the CheckMate-9ER trial, the next steps for nivolumab/cabozantinib, and other cabozantinib regimens under exploration.
The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.
Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive cancers arising from the head and neck.
Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.
Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.
Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.
Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.
Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.
Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.
In our exclusive interview, Jacob Sands, MD, discusses the FDA approval of lurbinectedin in small cell lung cancer and shed light on key findings from the phase 2 basket trial that served as the basis for the approval.
